Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04314531 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
A Phase 3 study of Active Psoriatic Arthritis, sponsored by Sun Pharmaceutical Industries Limited.
- Active
- Registry status
- Phase 3
- Development phase
- 296
- Enrollment target
- 20
- Study locations
NCT04314531 is a Phase 3 study of Active Psoriatic Arthritis that is active but no longer recruiting, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 296 participants, roughly in line with the 323-participant average among 3 other Active Psoriatic Arthritis trials with a reported enrollment target. The trial reports 20 study locations across 12 states.
The verdict
NCT04314531, a Phase 3 study of Active Psoriatic Arthritis, is active but no longer recruiting, sponsored by Sun Pharmaceutical Industries Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 296 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .
Conditions Studied
Interventions
- DRUG TILD
- DRUG matching placebo injections
Study Locations (20)
Other
- Sunpharma Site 64 - Brno
- Sunpharma Site 97 - Prague
- Sunpharma Site 63 - Zlín
- Sunpharma Site 73 - Berlin
- Sunpharma Site 92 - Herne
Florida
- Sunpharma site no. 04 - Miami Beach
- Sunpharma site no. 02 - New Port Richey
- Sunpharma site no. 07 - Tamarac
Texas
- Sunpharma site no. 09 - Lubbock
- Sunpharma site no. 03 - San Antonio
- Sunpharma site no. 01 - Tomball
California
- Sunpharma site no. 12 - Covina
Missouri
- Sunpharma site no. 05 - Springfield
Nebraska
- Sunpharma site no. 10 - Lincoln
South Carolina
- Sunpharma site no. 11 - Greenville
Washington
- Sunpharma site no. 06 - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04314531
The ClinicalTrials.gov registry entry for NCT04314531 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 323-participant average among 3 other Active Psoriatic Arthritis trials with a reported enrollment target. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Active Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which TILD is the first listed.
NCT04314531 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04314531 about?
NCT04314531 is a clinical study titled "Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)". This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .
What is the current status of trial NCT04314531?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 296 participants. The study started on 2020-07-01. Estimated completion is 2026-04.
What conditions does trial NCT04314531 study?
This clinical trial studies the following conditions: Active Psoriatic Arthritis.
What interventions are being tested in trial NCT04314531?
The interventions under investigation include: TILD (DRUG), matching placebo injections (DRUG).
Who is sponsoring clinical trial NCT04314531?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04314531 being conducted?
This trial has 20 study locations across California, Florida, Missouri, Nebraska, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Active Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
COMPLETED · Phase 3
-
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
COMPLETED · Phase 3
-
Efficacy and Safety Study of SUNPG1623
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.